The FDA is investigating potential side effects of several treatments, including Eli Lilly and Co.'s blood thinner Effient and Sanofi-Aventis' heart drug Multaq. The agency said it is looking at cases of thrombotic thrombocytopenic purpura and congestive heart failure in patients treated with Effient and Multaq, respectively.

Full Story:

Related Summaries